Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro

Christine Dufès, Céline Alleaume, Alicia Montoni, Jean-Christophe Olivier, Jean-Marc Muller

Research output: Contribution to journalArticle

  • 18 Citations

Abstract

The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine/isoleucine (PHI). The aim of this work was to investigate the effect of these peptides on the growth of the rat glioblastoma cell line C6 in vitro. We also sought to determine which binding sites were correlated with the effects observed. Proliferation studies performed by means of a CyQuant trade mark assay showed that VIP and PACAP strongly stimulated C6 cell proliferation at most of the concentrations tested, whereas PHI increased cell proliferation only when associated with VIP. Two growth hormone-releasing factor (GRF) derivatives and the VIP antagonist hybrid peptide neurotensin-VIP were able to inhibit VIP-induced cell growth stimulation, even at very low concentrations. Binding experiments carried out on intact cultured C6 cells, using 125I-labeled VIP and PACAP as tracers, revealed that the effects of the peptides on cell growth were correlated with the expression on C6 cells of polyvalent high-affinity VIP-PACAP binding sites and of a second subtype corresponding to very high-affinity VIP-selective binding species. The latter subtype, which interacted poorly with PACAP with a 10,000-fold lower affinity than VIP, might mediate the antagonist effects of neurotensin- VIP and of both GRF derivatives on VIP-induced cell growth stimulation.
LanguageEnglish
Pages91-102
Number of pages11
JournalJournal of Molecular Neuroscience
Volume21
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Vasoactive Intestinal Peptide
Glioblastoma
Peptides
Growth
Adenylyl Cyclases
Peptide PHI
Growth Hormone-Releasing Hormone
Neurotensin
In Vitro Techniques
Binding Sites
Cell Proliferation
Cell Line
Neuropeptides
Glucagon
Cultured Cells

Keywords

  • C6 glioblastoma
  • vasoactive intestinal peptide
  • cell growth
  • cancer
  • VIP antagonist
  • pharmacology
  • biomedical sciences

Cite this

Dufès, Christine ; Alleaume, Céline ; Montoni, Alicia ; Olivier, Jean-Christophe ; Muller, Jean-Marc. / Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. In: Journal of Molecular Neuroscience. 2003 ; Vol. 21, No. 2. pp. 91-102
@article{4f3804b3b98149b7bcc0421c61ad8d10,
title = "Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro",
abstract = "The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine/isoleucine (PHI). The aim of this work was to investigate the effect of these peptides on the growth of the rat glioblastoma cell line C6 in vitro. We also sought to determine which binding sites were correlated with the effects observed. Proliferation studies performed by means of a CyQuant trade mark assay showed that VIP and PACAP strongly stimulated C6 cell proliferation at most of the concentrations tested, whereas PHI increased cell proliferation only when associated with VIP. Two growth hormone-releasing factor (GRF) derivatives and the VIP antagonist hybrid peptide neurotensin-VIP were able to inhibit VIP-induced cell growth stimulation, even at very low concentrations. Binding experiments carried out on intact cultured C6 cells, using 125I-labeled VIP and PACAP as tracers, revealed that the effects of the peptides on cell growth were correlated with the expression on C6 cells of polyvalent high-affinity VIP-PACAP binding sites and of a second subtype corresponding to very high-affinity VIP-selective binding species. The latter subtype, which interacted poorly with PACAP with a 10,000-fold lower affinity than VIP, might mediate the antagonist effects of neurotensin- VIP and of both GRF derivatives on VIP-induced cell growth stimulation.",
keywords = "C6 glioblastoma, vasoactive intestinal peptide, cell growth, cancer, VIP antagonist, pharmacology, biomedical sciences",
author = "Christine Duf{\`e}s and C{\'e}line Alleaume and Alicia Montoni and Jean-Christophe Olivier and Jean-Marc Muller",
year = "2003",
doi = "10.1385/JMN:21:2:91",
language = "English",
volume = "21",
pages = "91--102",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
number = "2",

}

Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. / Dufès, Christine; Alleaume, Céline; Montoni, Alicia; Olivier, Jean-Christophe; Muller, Jean-Marc.

In: Journal of Molecular Neuroscience, Vol. 21, No. 2, 2003, p. 91-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro

AU - Dufès,Christine

AU - Alleaume,Céline

AU - Montoni,Alicia

AU - Olivier,Jean-Christophe

AU - Muller,Jean-Marc

PY - 2003

Y1 - 2003

N2 - The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine/isoleucine (PHI). The aim of this work was to investigate the effect of these peptides on the growth of the rat glioblastoma cell line C6 in vitro. We also sought to determine which binding sites were correlated with the effects observed. Proliferation studies performed by means of a CyQuant trade mark assay showed that VIP and PACAP strongly stimulated C6 cell proliferation at most of the concentrations tested, whereas PHI increased cell proliferation only when associated with VIP. Two growth hormone-releasing factor (GRF) derivatives and the VIP antagonist hybrid peptide neurotensin-VIP were able to inhibit VIP-induced cell growth stimulation, even at very low concentrations. Binding experiments carried out on intact cultured C6 cells, using 125I-labeled VIP and PACAP as tracers, revealed that the effects of the peptides on cell growth were correlated with the expression on C6 cells of polyvalent high-affinity VIP-PACAP binding sites and of a second subtype corresponding to very high-affinity VIP-selective binding species. The latter subtype, which interacted poorly with PACAP with a 10,000-fold lower affinity than VIP, might mediate the antagonist effects of neurotensin- VIP and of both GRF derivatives on VIP-induced cell growth stimulation.

AB - The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine/isoleucine (PHI). The aim of this work was to investigate the effect of these peptides on the growth of the rat glioblastoma cell line C6 in vitro. We also sought to determine which binding sites were correlated with the effects observed. Proliferation studies performed by means of a CyQuant trade mark assay showed that VIP and PACAP strongly stimulated C6 cell proliferation at most of the concentrations tested, whereas PHI increased cell proliferation only when associated with VIP. Two growth hormone-releasing factor (GRF) derivatives and the VIP antagonist hybrid peptide neurotensin-VIP were able to inhibit VIP-induced cell growth stimulation, even at very low concentrations. Binding experiments carried out on intact cultured C6 cells, using 125I-labeled VIP and PACAP as tracers, revealed that the effects of the peptides on cell growth were correlated with the expression on C6 cells of polyvalent high-affinity VIP-PACAP binding sites and of a second subtype corresponding to very high-affinity VIP-selective binding species. The latter subtype, which interacted poorly with PACAP with a 10,000-fold lower affinity than VIP, might mediate the antagonist effects of neurotensin- VIP and of both GRF derivatives on VIP-induced cell growth stimulation.

KW - C6 glioblastoma

KW - vasoactive intestinal peptide

KW - cell growth

KW - cancer

KW - VIP antagonist

KW - pharmacology

KW - biomedical sciences

U2 - 10.1385/JMN:21:2:91

DO - 10.1385/JMN:21:2:91

M3 - Article

VL - 21

SP - 91

EP - 102

JO - Journal of Molecular Neuroscience

T2 - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 2

ER -